79 related articles for article (PubMed ID: 8729971)
21. Cyclin D1-negative blastoid mantle cell lymphoma identified by SOX11 expression.
Zeng W; Fu K; Quintanilla-Fend L; Lim M; Ondrejka S; Hsi ED
Am J Surg Pathol; 2012 Feb; 36(2):214-9. PubMed ID: 22251940
[TBL] [Abstract][Full Text] [Related]
22. The cytomorphological spectrum of mantle cell lymphoma is reflected by distinct biological features.
Ott G; Kalla J; Hanke A; Müller JG; Rosenwald A; Katzenberger T; Kretschmar R; Kreipe H; Müller-Hermelink HK
Leuk Lymphoma; 1998 Dec; 32(1-2):55-63. PubMed ID: 10037001
[TBL] [Abstract][Full Text] [Related]
23. Mutant p53-induced immortalization of primary human mammary epithelial cells.
Gao Q; Hauser SH; Liu XL; Wazer DE; Madoc-Jones H; Band V
Cancer Res; 1996 Jul; 56(13):3129-33. PubMed ID: 8674072
[TBL] [Abstract][Full Text] [Related]
24. The mdm-2 oncogene can overcome wild-type p53 suppression of transformed cell growth.
Finlay CA
Mol Cell Biol; 1993 Jan; 13(1):301-6. PubMed ID: 8417333
[TBL] [Abstract][Full Text] [Related]
25. Molecular pathology of primary and metastatic ductal pancreatic lesions: analyses of mutations and expression of the p53, mdm-2, and p21/WAF-1 genes in sporadic and familial lesions.
Ruggeri BA; Huang L; Berger D; Chang H; Klein-Szanto AJ; Goodrow T; Wood M; Obara T; Heath CW; Lynch H
Cancer; 1997 Feb; 79(4):700-16. PubMed ID: 9024708
[TBL] [Abstract][Full Text] [Related]
26. Strong correlation of basement membrane degradation with p53 inactivation and/or MDM2 overexpression in superficial urothelial carcinomas.
Ozdemir E; Kakehi Y; Okuno H; Habuchi T; Okada Y; Yoshida O
J Urol; 1997 Jul; 158(1):206-11. PubMed ID: 9186361
[TBL] [Abstract][Full Text] [Related]
27. mdm-2 oncogene expression in non-Hodgkin's lymphomas.
Kawamata N; Miller C; Levy V; Shintaku IP; Koeffler HP; Said JW
Diagn Mol Pathol; 1996 Mar; 5(1):33-8. PubMed ID: 8919543
[TBL] [Abstract][Full Text] [Related]
28. Alterations of the cyclin D1/p16-pRB pathway in mantle cell lymphoma.
Dreyling MH; Bullinger L; Ott G; Stilgenbauer S; Müller-Hermelink HK; Bentz M; Hiddemann W; Döhner H
Cancer Res; 1997 Oct; 57(20):4608-14. PubMed ID: 9377576
[TBL] [Abstract][Full Text] [Related]
29. p53 protein expression in breast carcinomas. Comparative study with the wild type p53 induced proteins mdm2 and p21/waf1.
Giannikaki E; Kouvidou C; Tzardi M; Stefanaki K; Koutsoubi K; Gregoriou M; Zois E; Kakolyris S; Mavroudi C; Delides G; Georgoulias V; Kanavaros P
Anticancer Res; 1997; 17(3C):2123-7. PubMed ID: 9216675
[TBL] [Abstract][Full Text] [Related]
30. Expression of the cell-cycle-related proteins E2F-1, p53, mdm-2, p21waf-1, and Ki-67 in multiple myeloma: correlation with cyclin-D1 immunoreactivity.
Lai R; Medeiros LJ; Wilson CS; Sun NC; Koo C; McCourty A; Brynes RK
Mod Pathol; 1998 Jul; 11(7):642-7. PubMed ID: 9688185
[TBL] [Abstract][Full Text] [Related]
31. BCL-1 (PRAD-1/cyclin D-1) overexpression distinguishes the blastoid variant of mantle cell lymphoma from B-lineage lymphoblastic lymphoma.
Soslow RA; Zukerberg LR; Harris NL; Warnke RA
Mod Pathol; 1997 Aug; 10(8):810-7. PubMed ID: 9267824
[TBL] [Abstract][Full Text] [Related]
32. Predictive value of cell cycle markers p53, MDM2, p21, and Ki-67 in superficial bladder tumor recurrence.
Pfister C; Moore L; Allard P; Larue H; Lacombe L; Têtu B; Meyer F; Fradet Y
Clin Cancer Res; 1999 Dec; 5(12):4079-84. PubMed ID: 10632343
[TBL] [Abstract][Full Text] [Related]
33. Molecular control of the cell cycle in cancer: biological and clinical aspects.
Møller MB
Dan Med Bull; 2003 May; 50(2):118-38. PubMed ID: 12812137
[TBL] [Abstract][Full Text] [Related]
34. [TP53 gene aberrations in chondromatous neoplasms: correlation with immunohistochemical p53 accumulation and MDM2 expression].
Blasenbreu S; Baretton GB; Bender C; Haas CJ; Diebold J; Löhrs U
Verh Dtsch Ges Pathol; 1998; 82():284-9. PubMed ID: 10095448
[TBL] [Abstract][Full Text] [Related]
35. Establishment and comprehensive analysis of a new human transformed follicular lymphoma B cell line, Tat-1.
Denyssevych T; Lestou VS; Knesevich S; Robichaud M; Salski C; Tan R; Gascoyne RD; Horsman DE; Mayer LD
Leukemia; 2002 Feb; 16(2):276-83. PubMed ID: 11840295
[TBL] [Abstract][Full Text] [Related]
36. Overexpression of MDM2, due to enhanced translation, results in inactivation of wild-type p53 in Burkitt's lymphoma cells.
Capoulade C; Bressac-de Paillerets B; Lefrère I; Ronsin M; Feunteun J; Tursz T; Wiels J
Oncogene; 1998 Mar; 16(12):1603-10. PubMed ID: 9569028
[TBL] [Abstract][Full Text] [Related]
37. Bcl-1/cyclin D1 in malignant lymphoma.
de Boer CJ; van Krieken JH; Schuuring E; Kluin PM
Ann Oncol; 1997; 8 Suppl 2():109-17. PubMed ID: 9209653
[TBL] [Abstract][Full Text] [Related]
38. [WAF1/CIP1/p21 gene in wild type p53 and mutant p53 human breast cancer cell lines in relation to its cytobiological features].
Jiang M; Shao Z; Wu J
Zhonghua Zhong Liu Za Zhi; 1998 May; 20(3):181-4. PubMed ID: 10921001
[TBL] [Abstract][Full Text] [Related]
39. Oncogene alterations in carcinomas of the uterine cervix: overexpression of the epidermal growth factor receptor is associated with poor prognosis.
Kersemaekers AM; Fleuren GJ; Kenter GG; Van den Broek LJ; Uljee SM; Hermans J; Van de Vijver MJ
Clin Cancer Res; 1999 Mar; 5(3):577-86. PubMed ID: 10100709
[TBL] [Abstract][Full Text] [Related]
40. Immunohistochemical and molecular evaluation of the mdm-2 gene product in bronchogenic carcinoma.
Gorgoulis VG; Rassidakis GZ; Karameris AM; Papastamatiou H; Trigidou R; Veslemes M; Rassidakis AN; Kittas C
Mod Pathol; 1996 May; 9(5):544-54. PubMed ID: 8733770
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]